Table S2. Estimated costs of each stage of cervical lesions throughout disease courses ().

Stages	Courses of disease	Median total costs (IQR)	Weight (%)	Reference	Estimated total costs (IQR)
IQR, interquartile range; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
Rural
LSIL	Diagnosis	48.3 (21.4−127.1)	100	Assumed	459.0 (167.7−1,330.3)
	Initial treatment	171.4 (56.6−555.8)	100	Assumed
	Follow-up	246.7 (92.4−667.5)	97.0	Assumed
HSIL	Diagnosis	88.2 (77.1−215.3)	100	Assumed	1,230.5 (560.6−2,104.5)
	Initial treatment	717.1 (374.3−1,097.8)	100	Assumed
	Follow-up	408.3 (98.5−763.1)	97.0	Assumed
	Recurrence/progress	1,814.6 (847.0−3,201.3)	1.6	(18)
Urban
LSIL	Diagnosis	285.7 (170.1−481.5)	100	Assumed	1,637.7 (956.4−2,669.2)
	Initial treatment	684.4 (379.1−1,067.5)	100	Assumed
	Follow-up	688.2 (419.7−1,154.9)	97.0	Assumed
HSIL	Diagnosis	293.6 (172.1−497.1)	100	Assumed	2,467.1 (1,579.1−3,762.3)
	Initial treatment	1,250.7 (862.7−1,698.2)	100	Assumed
	Follow-up	921.4 (547.1−1,562.7)	97.0	Assumed
	Recurrence/progress	1,814.6 (847.0−3,201.3)	1.6	(18)
National
IA	Diagnosis	354.6 (170.9−749.8)	100	(19)	15,034.9 (11,083.4−21,632.4)
	Initial treatment	3,863.1 (3,229.9−5,490.8)	100	(19)
	Chemoradiotherapy	14,313.8 (10,535.9−19,690.5)	63.5	(19)
	Follow-up	1,657.7 (927.4−2,837.8)	97.0	(20)
	Recurrence/metastasis	4,288.0 (3,313.4−4,840.4)	2.8	(21)
IB	Diagnosis	371.4 (179.3−815.1)	100	(19)	19,438.6 (14,060.0−26,505.9)
	Initial treatment	6,554.2 (5,243.3−8,002.1)	100	(19)
	Chemoradiotherapy	12,739.1 (10,214.8−16,915.1)	63.5	(19)
	Follow-up	3,418.4 (1,621.5−6,186.1)	97.0	(20)
	Recurrence/metastasis	10,861.5 (5,668.7−9,284.8)	10.2	(21)
IIA	Diagnosis	328.6 (185.7−580.0)	100	(19)	22,968.8 (16,068.8−34,615.9)
	Initial treatment	6,605.8 (4,974.9−9,751.4)	100	(19)
	Chemoradiotherapy	14,701.9 (10,333.8−19,216.9)	79.6	(19)
	Follow-up	2,448.4 (1,256.7−5,360.0)	97.0	(20)
	Recurrence/metastasis	11,787.7 (8,816.4−22,823.8)	16.6	(21)
IIB	Diagnosis	487.9 (213.3−1,449.6)	100	(19)	26,936.0 (18,176.6−41,386.0)
	Initial treatment	7,481.9 (5,023.7−11,424.8)	100	(19)
	Chemoradiotherapy	13,698.6 (10,579.8−17,820.3)	79.6	(19)
	Follow-up	4,877.0 (1,997.2−9,014.8)	95.6	(22)
	Recurrence/metastasis	15,739.3 (12,077.2−26,428.0)	21.6	(21)
III	Diagnosis	343.0 (228.5−717.0)	100	(19)	26,243.6 (17,208.5−39,075.6)
	Initial treatment	15,016.7 (11,269.3−20,222.1)	100	(19)
	Follow-up	4,989.8 (2,054.0−10,158.9)	95.6	(22)
	Recurrence/metastasis	17,772.6 (10,892.9−24,490.1)	34.4	(21)
IV	Diagnosis	792.7 (214.6−1,339.0)	100	(19)	28,421.5 (17,869.0−50,718.4)
	Initial treatment	12,882.5 (9,083.9−20,620.9)	100	(19)
	Follow-up	9,239.6 (4,391.1−19,633.8)	95.6	(22)
	Recurrence/metastasis	11,263.3 (8,328.8−19,025.9)	52.5	(21)